Hypofractionated Partial Breast Irradiation With Intensity-Modulated Radiotherapy in Early Breast Cancer or Carcinoma In Situ: An Investigational Short-Term Analysis.

IF 2.2 4区 医学 Q3 ONCOLOGY
Journal of Breast Cancer Pub Date : 2024-04-01 Epub Date: 2024-03-26 DOI:10.4048/jbc.2023.0296
Nam Kyu Kang, Soo-Yoon Sung, Sung Hwan Kim, Ye Won Jeon, Young Jin Suh, Jong Hoon Lee
{"title":"Hypofractionated Partial Breast Irradiation With Intensity-Modulated Radiotherapy in Early Breast Cancer or Carcinoma <i>In Situ</i>: An Investigational Short-Term Analysis.","authors":"Nam Kyu Kang, Soo-Yoon Sung, Sung Hwan Kim, Ye Won Jeon, Young Jin Suh, Jong Hoon Lee","doi":"10.4048/jbc.2023.0296","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to analyze the treatment outcomes and adverse effects of moderately hypofractionated partial breast irradiation (PBI) in patients with early breast cancer.</p><p><strong>Methods: </strong>In total, 473 patients with early breast cancer or carcinoma <i>in situ</i> were diagnosed with Tis or T1N0 disease and underwent PBI following breast-conserving surgery. All histologic tumor types, close surgical margins within 1 mm of the tumor, and multifocal tumors were included in this study. A radiation dose of 50 Gy in 20 fractions was delivered over 4 weeks using intensity-modulated radiotherapy technique. Dosimetric data, recurrence patterns, survival outcomes, and adverse events were retrospectively analyzed.</p><p><strong>Results: </strong>During a median follow-up of 28.9 months, seven patients (1.5%) experienced ipsilateral breast tumor recurrence (IBTR). Two patients had regional recurrence, four patients developed contralateral breast cancer, and no distant metastases were observed. The locoregional recurrence rate in the ipsilateral breast was 1.8%. Two deaths occurred during the follow-up period, but were not attributed to breast cancer. The 2-year disease-free survival and 2-year overall survival rates were was 94.0% and 99.8%, respectively. Acute adverse events occurred in 131 patients (27.1%), and were distributed among all grades, with only two patients (0.4%) experiencing grade 3 events. Late adverse events were noted in 16 patients (3.4%), and were distributed among all grades, including grade 3 events in four patients (0.8%). No grade 4 or 5 events were observed.</p><p><strong>Conclusion: </strong>Hypofractionated PBI demonstrated favorable IBTR rates in patients with early breast cancer, with low incidence of acute and late toxicities in the short-term analysis.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11065498/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Breast Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4048/jbc.2023.0296","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/26 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: This study aimed to analyze the treatment outcomes and adverse effects of moderately hypofractionated partial breast irradiation (PBI) in patients with early breast cancer.

Methods: In total, 473 patients with early breast cancer or carcinoma in situ were diagnosed with Tis or T1N0 disease and underwent PBI following breast-conserving surgery. All histologic tumor types, close surgical margins within 1 mm of the tumor, and multifocal tumors were included in this study. A radiation dose of 50 Gy in 20 fractions was delivered over 4 weeks using intensity-modulated radiotherapy technique. Dosimetric data, recurrence patterns, survival outcomes, and adverse events were retrospectively analyzed.

Results: During a median follow-up of 28.9 months, seven patients (1.5%) experienced ipsilateral breast tumor recurrence (IBTR). Two patients had regional recurrence, four patients developed contralateral breast cancer, and no distant metastases were observed. The locoregional recurrence rate in the ipsilateral breast was 1.8%. Two deaths occurred during the follow-up period, but were not attributed to breast cancer. The 2-year disease-free survival and 2-year overall survival rates were was 94.0% and 99.8%, respectively. Acute adverse events occurred in 131 patients (27.1%), and were distributed among all grades, with only two patients (0.4%) experiencing grade 3 events. Late adverse events were noted in 16 patients (3.4%), and were distributed among all grades, including grade 3 events in four patients (0.8%). No grade 4 or 5 events were observed.

Conclusion: Hypofractionated PBI demonstrated favorable IBTR rates in patients with early breast cancer, with low incidence of acute and late toxicities in the short-term analysis.

早期乳腺癌或原位癌的部分乳腺低分次放射治疗与调强放疗:一项研究性短期分析。
目的:本研究旨在分析早期乳腺癌患者接受适度低分次乳腺部分照射(PBI)的治疗效果和不良反应:共有 473 例早期乳腺癌或原位癌患者被诊断为 Tis 或 T1N0 病变,并在保乳手术后接受了 PBI 治疗。所有组织学肿瘤类型、手术切缘在肿瘤周围1毫米以内以及多灶性肿瘤均被纳入本研究。采用调强放疗技术,在4周内分20次给予50 Gy的放射剂量。对剂量数据、复发模式、生存结果和不良事件进行了回顾性分析:在中位 28.9 个月的随访期间,7 名患者(1.5%)出现同侧乳腺肿瘤复发(IBTR)。两名患者出现局部复发,四名患者出现对侧乳腺癌,未发现远处转移。同侧乳腺局部复发率为1.8%。随访期间有两人死亡,但并非死于乳腺癌。2年无病生存率和2年总生存率分别为94.0%和99.8%。131名患者(27.1%)发生了急性不良反应,这些不良反应分布在各个等级,只有2名患者(0.4%)发生了3级不良反应。16名患者(3.4%)出现了晚期不良反应,不良反应分布在各个级别,其中4名患者(0.8%)出现了3级不良反应。没有观察到4级或5级事件:结论:低分量 PBI 在早期乳腺癌患者中表现出良好的 IBTR 率,短期分析中急性和晚期毒性反应发生率较低。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Breast Cancer
Journal of Breast Cancer 医学-肿瘤学
CiteScore
3.80
自引率
4.20%
发文量
43
审稿时长
6-12 weeks
期刊介绍: The Journal of Breast Cancer (abbreviated as ''J Breast Cancer'') is the official journal of the Korean Breast Cancer Society, which is issued quarterly in the last day of March, June, September, and December each year since 1998. All the contents of the Journal is available online at the official journal website (http://ejbc.kr) under open access policy. The journal aims to provide a forum for the academic communication between medical doctors, basic science researchers, and health care professionals to be interested in breast cancer. To get this aim, we publish original investigations, review articles, brief communications including case reports, editorial opinions on the topics of importance to breast cancer, and welcome new research findings and epidemiological studies, especially when they contain a regional data to grab the international reader''s interest. Although the journal is mainly dealing with the issues of breast cancer, rare cases among benign breast diseases or evidence-based scientifically written articles providing useful information for clinical practice can be published as well.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信